论文部分内容阅读
目的探讨曲美他嗪治疗不稳定性心绞痛临床疗效。方法 2009年1月至2011年1月诊治的不稳定性心绞痛患者218例,随机分为常规治疗组110例,曲美他嗪组108例,观察两组临床疗效。结果曲美他嗪组总有效率91.66%,常规治疗组75.45%,两组总有效率比较P<0.05有统计学差异性。结论曲美他嗪在不稳定性心绞痛治疗中,能够缓解心绞痛、减少发作次数、缩短持续时间、减少再住院率、耐受性良好、提高患者的生活质量的新型代谢类抗心绞痛药物。
Objective To investigate the clinical efficacy of trimetazidine in the treatment of unstable angina pectoris. Methods 218 patients with unstable angina who were diagnosed and treated from January 2009 to January 2011 were randomly divided into routine treatment group (n = 110) and trimetazidine group (n = 108). The clinical effects were observed. Results The total effective rate was 91.66% in the trimetazidine group and 75.45% in the conventional treatment group. The total effective rate in the two groups was statistically significant compared with P <0.05. Conclusion Trimetazidine in the treatment of unstable angina can relieve angina pectoris, reduce the number of attacks, shorten the duration, reduce the rate of rehospitalization, good tolerance, and improve the quality of life of patients with a new type of metabolic anti-angina drugs.